Patent Expirations AbbVie Investors Need to Watch

At this point, every AbbVie  (NYSE: ABBV  ) investor knows about the company's reliance on its blockbuster drug Humira. The drug accounts for around half of the company's total sales and was one of its main growth drivers last quarter. While most investors are wondering what will happen to this drug's sales after it loses patent protection in 2016, some may forget that the company has other drugs that are poised to lose market exclusivity in the coming years. In the following segment, health care analysts David Williamson and Max Macaluso discuss the upcoming patent expirations that AbbVie investors need to watch.

More Compelling Companies
One of the best parts of owning big pharma stocks like AbbVie is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The relevant video segment can be found between 5:10 and 6:59.


Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 17, 2013, at 11:35 AM, mstanfordus wrote:

    Generics for biologic drugs like Humira are by no means a slam dunk. Bayer has blocked generics for premara for decades. (Made from urine of pregnant horses)

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2641338, ~/Articles/ArticleHandler.aspx, 12/22/2014 4:38:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement